Skip to content

TRANSPHORM, INC.

CIK 0001715768

← back to feed
Revenue (TTM)
$20.06M
−31.3% YoY Q3 Feb 2024
Net Income (TTM)
−$35.04M
−199.0% YoY Q3 Feb 2024
EPS Diluted (TTM)
−$0.72
−145.5% YoY Q3 Feb 2024
Gross Margin
3.3%
Q3 Feb 2024
Operating Margin
-160.0%
Q3 Feb 2024
Net Margin
-174.7%
Q3 Feb 2024
Free Cash Flow (TTM)
−$10.76M
Q3 Feb 2024
Cash
$7.95M
Q3 Feb 2024
Total Debt
$12.18M
Q3 Feb 2024
Shares Outstanding
63.27M sh
Q3 Feb 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings